Related Experiment Video

Updated: May 25, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer

Vera Hirsh1

  • 1Medical Oncology Department, MUHC Royal Victoria Hospital, 687 Pine Avenue West, Suite A3.04, Montreal, Quebec H3A 1A1, vera.hirsh@muhc.mcgill.ca.

Current Oncology (Toronto, Ont.)
|February 14, 2012
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Non-small-cell lung canceregfr mutationerlotinibgefitinib

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...